- Home
- OABI vs DERM Comparison
OABI vs DERM Comparison
Compare OABI & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- DERM
- Stock Information
- Founded
- OABI 2012
- DERM 2014
- Country
- OABI United States
- DERM United States
- Employees
- OABI N/A
- DERM N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- OABI Health Care
- DERM Health Care
- Exchange
- OABI Nasdaq
- DERM Nasdaq
- Market Cap
- OABI 227.4M
- DERM 190.7M
- IPO Year
- OABI N/A
- DERM 2021
- Fundamental
- Price
- OABI $1.66
- DERM $7.54
- Analyst Decision
- OABI Strong Buy
- DERM Strong Buy
- Analyst Count
- OABI 3
- DERM 3
- Target Price
- OABI $6.67
- DERM $12.67
- AVG Volume (30 Days)
- OABI 595.9K
- DERM 92.2K
- Earning Date
- OABI 11-11-2025
- DERM 11-11-2025
- Dividend Yield
- OABI N/A
- DERM N/A
- EPS Growth
- OABI N/A
- DERM N/A
- EPS
- OABI N/A
- DERM N/A
- Revenue
- OABI $23,027,000.00
- DERM $56,397,000.00
- Revenue This Year
- OABI N/A
- DERM $26.25
- Revenue Next Year
- OABI $48.74
- DERM $52.96
- P/E Ratio
- OABI N/A
- DERM N/A
- Revenue Growth
- OABI 6.05
- DERM N/A
- 52 Week Low
- OABI $1.22
- DERM $3.54
- 52 Week High
- OABI $4.87
- DERM $8.90
- Technical
- Relative Strength Index (RSI)
- OABI 49.38
- DERM 59.93
- Support Level
- OABI $1.58
- DERM $6.85
- Resistance Level
- OABI $1.72
- DERM $7.45
- Average True Range (ATR)
- OABI 0.08
- DERM 0.30
- MACD
- OABI 0.02
- DERM 0.04
- Stochastic Oscillator
- OABI 65.15
- DERM 100.00
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.